Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2011

01-10-2011 | Review

Cross-talk and modulation of signaling between somatostatin and growth factor receptors

Author: Ujendra Kumar

Published in: Endocrine | Issue 2/2011

Login to get access

Abstract

The process of homo- and/or heterodimerization of G-protein coupled receptors (GPCRs) and receptor tyrosine kinase (RTK) families are crucial for implicating the fundamental properties of receptor proteins including receptor expression, trafficking, and desensitization as well as signal transduction. The members of GPCR and RTK family constitute largest cell surface receptor proteins and regulate physiological functions of cells in response to external and internal stimuli. Notably, GPCRs and RTKs play major role in regulation of several key cellular functions which are associated with several pathological conditions including cancer biology, neurodegenerative and cardiovascular diseases. The focus of this review is to highlight the recent findings on the possible cross-talk between somatostatin receptors (members of GPCR family) and growth factor receptors like epidermal growth factor receptors (members of RTK family). Furthermore, functional consequences of such an interaction in modulation of signaling pathways linked to pathological conditions specifically in cancer are discussed.
Literature
1.
D. Fotiadis, Y. Liang, S. Filipek, D.A. Saperstein, A. Engel, K. Palczewski, Atomic-force microscopy: rhodopsin dimers in native disc membranes. Nature 421(6919), 127–128 (2003)PubMedCrossRef
2.
M. Bouvier, N. Heveker, R. Jockers, S. Marullo, G. Milligan, BRET analysis of GPCR oligomerization: newer does not mean better. Nat. Methods 4(1), 3–4 (2007). author reply 4PubMedCrossRef
3.
G. Milligan, G protein-coupled receptor dimerization: function and ligand pharmacology. Mol. Pharmacol. 66(1), 1–7 (2004)PubMedCrossRef
4.
U. Kumar, M. Grant, Somatostatin and somatostatin receptors. Results Probl. Cell Differ. 50, 137–184 (2010)PubMed
5.
Y. Yarden, M.X. Sliwkowski, Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2(2), 127–137 (2001)PubMedCrossRef
6.
7.
H. Daub, C. Wallasch, A. Lankenau, A. Herrlich, A. Ullrich, Signal characteristics of G protein-transactivated EGF receptor. EMBO J. 16(23), 7032–7044 (1997)PubMedCrossRef
8.
L.M. Luttrell, Y. Daaka, R.J. Lefkowitz, Regulation of tyrosine kinase cascades by G-protein-coupled receptors. Curr. Opin. Cell Biol. 11, 177–183 (1999)PubMedCrossRef
9.
F.S. Lee, M.V. Chao, Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proc. Natl. Acad. Sci. USA 98(6), 3555–3560 (2001)PubMedCrossRef
10.
K.L. Pierce, L.M. Luttrell, R.J. Lefkowitz, New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. Oncogene 20(13), 1532–1539 (2001)PubMedCrossRef
11.
P.O. Hackel, E. Zwick, N. Prenzel, A. Ullrich, Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr. Opin. Cell Biol. 11(2), 184–189 (1999)PubMedCrossRef
12.
B. Hellman, A. Lernmark, Inhibition of the in vitro secretion of insulin by an extract of pancreatic alpha-1 cells. Endocrinology 84(6), 1484–1488 (1969)PubMedCrossRef
13.
L. Krulich, A.P. Dhariwal, S.M. McCann, Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 83(4), 783–790 (1968)PubMedCrossRef
14.
Y.C. Patel, S. Reichlin, Somatostatin in hypothalamus, extrahypothalamic brain, and peripheral tissues of the rat. Endocrinology 102(2), 523–530 (1978)PubMedCrossRef
15.
16.
J. Epelbaum, P. Dournaud, M. Fodor, C. Viollet, The neurobiology of somatostatin. Crit. Rev. Neurobiol. 8(1–2), 25–44 (1994)PubMed
17.
Y.C. Patel, Molecular pharmacology of somatostatin receptor subtypes. J. Endocrinol. Invest. 20(6), 348–367 (1997)PubMed
18.
U. Kumar, D. Laird, C.B. Srikant, E. Escher, Y.C. Patel, Expression of the five somatostatin receptor (SSTR1–5) subtypes in rat pituitary somatotrophes: quantitative analysis by double-layer immunofluorescence confocal microscopy. Endocrinology 138(10), 4473–4476 (1997)PubMedCrossRef
19.
K.V. Sorensen, S.E. Christensen, A.P. Hansen, E. Pedersen, H. Orskov, Cerebrospinal fluid somatostatin inversely correlated with disease activity in multiple sclerosis. Lancet 1(8331), 988 (1983)PubMedCrossRef
20.
D. Hoyer, H. Lubbert, C. Bruns, Molecular pharmacology of somatostatin receptors. Naunyn Schmiedebergs Arch Pharmacol 350(5), 441–453 (1994)PubMedCrossRef
21.
A. Schonbrunn, H. Tashjian Jr., Characterization of functional receptors for somatostatin in rat pituitary cells in culture. J. Biol. Chem. 253(18), 6473–6483 (1978)PubMed
22.
K.D. Pfleger, K.A. Eidne, Monitoring the formation of dynamic G-protein-coupled receptor-protein complexes in living cells. Biochem. J. 385(Pt 3), 625–637 (2005)PubMed
23.
S. Bulenger, S. Marullo, M. Bouvier, Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol. Sci. 26(3), 131–137 (2005)PubMedCrossRef
24.
M. Duran-Prado, M.M. Malagon, F. Gracia-Navarro, J.P. Castano, Dimerization of G protein-coupled receptors: new avenues for somatostatin receptor signalling, control and functioning. Mol. Cell. Endocrinol. 286(1–2), 63–68 (2008)PubMedCrossRef
25.
J.M. Gripentrog, K.P. Kantele, A.J. Jesaitis, H.M. Miettinen, Experimental evidence for lack of homodimerization of the G protein-coupled human N-formyl peptide receptor. J. Immunol. 171(6), 3187–3193 (2003)PubMed
26.
B.H. Meyer, J.M. Segura, K.L. Martinez, R. Hovius, N. George, K. Johnsson, H. Vogel, FRET imaging reveals that functional neurokinin-1 receptors are monomeric and reside in membrane microdomains of live cells. Proc. Natl. Acad. Sci. USA 103(7), 2138–2143 (2006)PubMedCrossRef
27.
M. Grant, B. Collier, U. Kumar, Agonist-dependent dissociation of human somatostatin receptor 2 dimers: a role in receptor trafficking. J. Biol. Chem. 279(35), 36179–36183 (2004)PubMedCrossRef
28.
M. Pfeiffer, T. Koch, H. Schroder, M. Klutzny, S. Kirscht, H.J. Kreienkamp, V. Hollt, S. Schulz, Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J. Biol. Chem. 276(17), 14027–14036 (2001)PubMed
29.
M.A. Ayoub, C. Couturier, E. Lucas-Meunier, S. Angers, P. Fossier, M. Bouvier, R. Jockers, Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. J. Biol. Chem. 277(24), 21522–21528 (2002)PubMedCrossRef
30.
M. Rocheville, D.C. Lange, U. Kumar, R. Sasi, R.C. Patel, Y.C. Patel, Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J. Biol. Chem. 275(11), 7862–7869 (2000)PubMedCrossRef
31.
M. Grant, R.C. Patel, U. Kumar, The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors. J. Biol. Chem. 279(37), 38636–38643 (2004)PubMedCrossRef
32.
M. Duran-Prado, C. Bucharles, B.J. Gonzalez, R. Vazquez-Martinez, A.J. Martinez-Fuentes, S. Garcia-Navarro, S.J. Rhodes, H. Vaudry, M.M. Malagon, J.P. Castano, Porcine somatostatin receptor 2 displays typical pharmacological sst2 features but unique dynamics of homodimerization and internalization. Endocrinology 148(1), 411–421 (2007)PubMedCrossRef
33.
S.A. War, R.K. Somvanshi, U. Kumar, Somatostatin receptor-3 mediated intracellular signaling and apoptosis is regulated by its cytoplasmic terminal. Biochim. Biophys. Acta 1813(3), 390–402 (2011)PubMedCrossRef
34.
R.K. Somvanshi, S. Billova, G. Kharmate, P.S. Rajput, U. Kumar, C-tail mediated modulation of somatostatin receptor type-4 homo- and heterodimerizations and signaling. Cell. Signal. 21(9), 1396–1414 (2009)PubMedCrossRef
35.
A. Baragli, H. Alturaihi, H.L. Watt, A. Abdallah, U. Kumar, Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell. Signal. 19(11), 2304–2316 (2007)PubMedCrossRef
36.
M. Grant, H. Alturaihi, P. Jaquet, B. Collier, U. Kumar, Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol. Endocrinol. 22(10), 2278–2292 (2008)PubMedCrossRef
37.
M. Pfeiffer, T. Koch, H. Schroder, M. Laugsch, V. Hollt, S. Schulz, Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J. Biol. Chem. 277(22), 19762–19772 (2002)PubMedCrossRef
38.
M. Rocheville, D.C. Lange, U. Kumar, S.C. Patel, R.C. Patel, Y.C. Patel, Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288(5463), 154–157 (2000)PubMedCrossRef
39.
R.K. Somvanshi, N. Chaudhari, X. Qiu, U. Kumar, Heterodimerization of beta2 adrenergic receptor and somatostatin receptor 5: implications in modulation of signaling pathway. J. Mol. Signal. 6, 9 (2011)
40.
R.K. Somvanshi, S.A. War, N. Chaudhari, X. Qiu, U. Kumar, Receptor specific crosstalk and modulation of signaling upon heterodimerization between beta1-adrenergic receptor and somatostatin receptor-5. Cell. Signal. 23(5), 794–811 (2011)PubMedCrossRef
41.
G. Kharmate, P.S. Rajput, H.L. Watt, R.K. Somvanshi, N. Chaudhari, X. Qiu, U. Kumar, Dissociation of epidermal growth factor receptor and ErbB2 heterodimers in the presence of somatostatin receptor 5 modulate signaling pathways. Endocrinology 152(3), 931–945 (2011)PubMedCrossRef
42.
G. Kharmate, P.S. Rajput, H.L. Watt, R.K. Somvanshi, N. Chaudhari, X. Qiu, U. Kumar, Role of somatostatin receptor 1 and 5 on epidermal growth factor receptor mediated signaling. Biochim. Biophys. Acta 1813(6), 1172–1189 (2011)PubMedCrossRef
43.
H.L. Watt, G.D. Kharmate, U. Kumar, Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells. Cell. Signal. 21(3), 428–439 (2009)PubMedCrossRef
44.
M. Grant, U. Kumar, The role of G-proteins in the dimerisation of human somatostatin receptor types 2 and 5. Regul. Pept. 159(1–3), 3–8 (2010)PubMedCrossRef
45.
R.C. Patel, U. Kumar, D.C. Lamb, J.S. Eid, M. Rocheville, M. Grant, A. Rani, T. Hazlett, S.C. Patel, E. Gratton, Y.C. Patel, Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. Proc. Natl. Acad. Sci. USA 99(5), 3294–3299 (2002)PubMedCrossRef
46.
Y.C. Patel, M.T. Greenwood, A. Warszynska, R. Panetta, C.B. Srikant, All five cloned human somatostatin receptors (hSSTR1–5) are functionally coupled to adenylyl cyclase. Biochem. Biophys. Res. Commun. 198(2), 605–612 (1994)PubMedCrossRef
47.
M.A. Olayioye, R.M. Neve, H. Lane, N.E. Hynes, The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19(13), 3159–3167 (2000)PubMedCrossRef
48.
D.C. Lev, L.S. Kim, V. Melnikova, M. Ruiz, H.N. Ananthaswamy, J.E. Price, Dual blockade of EGFR and ERK1/2 phosphorylation potentiates growth inhibition of breast cancer cells. Br. J. Cancer 91(4), 795–802 (2004)PubMed
49.
S. Okubo, J. Kurebayashi, T. Otsuki, Y. Yamamoto, K. Tanaka, H. Sonoo, Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182, 780) in breast cancer cells. Br. J. Cancer 90(1), 236–244 (2004)PubMedCrossRef
50.
A. deFazio, Y.E. Chiew, R.L. Sini, P.W. Janes, R.L. Sutherland, Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int. J. Cancer 87(4), 487–498 (2000)PubMedCrossRef
51.
52.
H.K. Gan, M. Lappas, D.X. Cao, A. Cvrljevdic, A.M. Scott, T.G. Johns, Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalization. J. Cell Mol. Med. 13(9B), 3993–4001 (2009)PubMedCrossRef
53.
D. Gerber, N. Sal-Man, Y. Shai, Two motifs within a transmembrane domain, one for homodimerization and the other for heterodimerization. J. Biol. Chem. 279(20), 21177–21182 (2004)PubMedCrossRef
54.
A.W. Burgess, H.S. Cho, C. Eigenbrot, K.M. Ferguson, T.P. Garrett, D.J. Leahy, M.A. Lemmon, M.X. Sliwkowski, C.W. Ward, S. Yokoyama, An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell 12(3), 541–552 (2003)PubMedCrossRef
55.
T.P. Garrett, N.M. McKern, M. Lou, T.C. Elleman, T.E. Adams, G.O. Lovrecz, M. Kofler, R.N. Jorissen, E.C. Nice, A.W. Burgess, C.W. Ward, The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell 11(2), 495–505 (2003)PubMedCrossRef
56.
L.N. Klapper, M.H. Kirschbaum, M. Sela, Y. Yarden, Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer Res. 77, 25–79 (2000)PubMedCrossRef
57.
K.L. Carraway 3rd, L.C. Cantley, A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 78(1), 5–8 (1994)PubMedCrossRef
58.
J.L. Gilmore, D.J. Riese 2nd, secErbB4-26/549 antagonizes ligand-induced ErbB4 tyrosine phosphorylation. Oncol. Res. 14(11–12), 589–602 (2004)PubMed
59.
K.L. Carraway 3rd, S.P. Soltoff, A.J. Diamonti, L.C. Cantley, Heregulin stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts transfected with erbB2/neu and erbB3. J. Biol. Chem. 270(13), 7111–7116 (1995)PubMedCrossRef
60.
B.D. Cohen, P.A. Kiener, J.M. Green, L. Foy, H.P. Fell, K. Zhang, The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. J. Biol. Chem. 271(48), 30897–30903 (1996)PubMedCrossRef
61.
P.M. Guy, J.V. Platko, L.C. Cantley, R.A. Cerione, K.L. Carraway 3rd, Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. Acad. Sci. USA 91(17), 8132–8136 (1994)PubMedCrossRef
62.
T. Holbro, R.R. Beerli, F. Maurer, M. Koziczak, C.F. Barbas 3rd, N.E. Hynes, The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA 100(15), 8933–8938 (2003)PubMedCrossRef
63.
R. Pinkas-Kramarski, M. Shelly, S. Glathe, B.J. Ratzkin, Y. Yarden, Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. J. Biol. Chem. 271(32), 19029–19032 (1996)PubMedCrossRef
64.
K. Zhang, J. Sun, N. Liu, D. Wen, D. Chang, A. Thomason, S.K. Yoshinaga, Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J. Biol. Chem. 271(7), 3884–3890 (1996)PubMedCrossRef
65.
J. Baulida, G. Carpenter, Heregulin degradation in the absence of rapid receptor-mediated internalization. Exp. Cell Res. 232(1), 167–172 (1997)PubMedCrossRef
66.
Z. Wang, L. Zhang, T.K. Yeung, X. Chen, Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation. Mol. Biol. Cell 10(5), 1621–1636 (1999)PubMed
67.
H. Waterman, I. Sabanai, B. Geiger, Y. Yarden, Alternative intracellular routing of ErbB receptors may determine signaling potency. J. Biol. Chem. 273(22), 13819–13827 (1998)PubMedCrossRef
68.
A.E. Lenferink, R. Pinkas-Kramarski, M.L. van de Poll, M.J. van Vugt, L.N. Klapper, E. Tzahar, H. Waterman, M. Sela, E.J. van Zoelen, Y. Yarden, Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J. 17(12), 3385–3397 (1998)PubMedCrossRef
69.
R. Zandi, A.B. Larsen, P. Andersen, M.T. Stockhausen, H.S. Poulsen, Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell. Signal. 19(10), 2013–2023 (2007)PubMedCrossRef
70.
E. Peles, R. Ben-Levy, E. Tzahar, N. Liu, D. Wen, Y. Yarden, Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J. 12(3), 961–971 (1993)PubMed
71.
G.D. Plowman, J.M. Green, J.M. Culouscou, G.W. Carlton, V.M. Rothwell, S. Buckley, Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature 366(6454), 473–475 (1993)PubMedCrossRef
72.
M.X. Sliwkowski, G. Schaefer, R.W. Akita, J.A. Lofgren, V.D. Fitzpatrick, A. Nuijens, B.M. Fendly, R.A. Cerione, R.L. Vandlen, K.L. Carraway 3rd, Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem. 269(20), 14661–14665 (1994)PubMed
73.
X. Qian, C.M. LeVea, J.K. Freeman, W.C. Dougall, M.I. Greene, Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation. Proc. Natl. Acad. Sci. USA 91(4), 1500–1504 (1994)PubMedCrossRef
74.
S. Gavi, D. Yin, E. Shumay, H.Y. Wang, C.C. Malbon, Insulin-like growth factor-I provokes functional antagonism and internalization of beta1-adrenergic receptors. Endocrinology 148(6), 2653–2662 (2007)PubMedCrossRef
75.
F.S. Lee, Novel crosstalk between G protein-coupled receptors and NMDA receptors. Exp. Neurol. 183(2), 269–272 (2003)PubMedCrossRef
76.
J.A. Garcia-Sainz, M.T. Romero-Avila, C. Medina Ldel, Dissecting how receptor tyrosine kinases modulate G protein-coupled receptor function. Eur. J. Pharmacol. 648(1–3), 1–5 (2010)PubMedCrossRef
77.
U. Kumar, S.I. Grigorakis, H.L. Watt, R. Sasi, L. Snell, P. Watson, S. Chaudhari, Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1–5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Res. Treat. 92(2), 175–186 (2005)PubMedCrossRef
78.
H.L. Watt, U. Kumar, Colocalization of somatostatin receptors and epidermal growth factor receptors in breast cancer cells. Cancer Cell. Int. 6, 5 (2006)PubMedCrossRef
79.
J. Held-Feindt, F. Forstreuter, T. Pufe, R. Mentlein, Influence of the somatostatin receptor sst2 on growth factor signal cascades in human glioma cells. Brain Res. Mol. Brain Res. 87(1), 12–21 (2001)PubMedCrossRef
80.
M.T. Lee, C. Liebow, A.R. Kamer, A.V. Schally, Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors. Proc. Natl. Acad. Sci. USA 88(5), 1656–1660 (1991)PubMedCrossRef
81.
S. Hart, O.M. Fischer, N. Prenzel, E. Zwick-Wallasch, M. Schneider, L. Hennighausen, A. Ullrich, GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways. Biol. Chem. 386(9), 845–855 (2005)PubMedCrossRef
82.
E.J. Filardo, J.A. Quinn, K.I. Bland, A.R. Frackelton Jr., Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol. 14(10), 1649–1660 (2000)PubMedCrossRef
83.
N. Prenzel, E. Zwick, H. Daub, M. Leserer, R. Abraham, C. Wallasch, A. Ullrich, EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402(6764), 884–888 (1999)PubMed
84.
H. Daub, F.U. Weiss, C. Wallash, A. Ullrich, Role of transactivation of the EGF receptor in signalling by G-protein coupled receptors. Nature 379, 557–560 (1996)PubMedCrossRef
85.
D. Darmoul, V. Gratio, H. Devaud, M. Laburthe, Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J. Biol. Chem. 279(20), 20927–20934 (2004)PubMedCrossRef
86.
H. Shankaran, H.S. Wiley, H. Resat, Modeling the effects of HER/ErbB1–3 coexpression on receptor dimerization and biological response. Biophys. J. 90(11), 3993–4009 (2006)PubMedCrossRef
87.
N.E. Willmarth, A. Baillo, M.L. Dziubinski, K. Wilson, D.J. Riese Ii, S.P. Ethier, Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop. Cell. Signal. 21(2), 212–219 (2009)PubMedCrossRef
88.
N. Moghal, P.W. Sternberg, Multiple positive and negative regulators of signaling by the EGF-receptor. Curr. Opin. Cell Biol. 11(2), 190–196 (1999)PubMedCrossRef
89.
W.J. Wu, S. Tu, R.A. Cerione, Activated Cdc42 sequesters c-Cbl and prevents EGF receptor degradation. Cell 114(6), 715–725 (2003)PubMedCrossRef
90.
T. Fukazawa, S. Miyake, V. Band, H. Band, Tyrosine phosphorylation of Cbl upon epidermal growth factor (EGF) stimulation and its association with EGF receptor and downstream signaling proteins. J. Biol. Chem. 271(24), 14554–14559 (1996)PubMedCrossRef
91.
T. Florio, S. Thellung, S. Arena, A. Corsaro, A. Bajetto, G. Schettini, P.J. Stork, Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2. J. Physiol. Paris 94(3–4), 239–250 (2000)PubMedCrossRef
92.
T. Florio, H. Yao, K.D. Carey, T.J. Dillon, P.J. Stork, Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1). Mol. Endocrinol. 13(1), 24–37 (1999)PubMedCrossRef
93.
H. Lahlou, N. Saint-Laurent, J.P. Esteve, A. Eychene, L. Pradayrol, S. Pyronnet, C. Susini, sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. J. Biol. Chem. 278(41), 39356–39371 (2003)PubMedCrossRef
94.
A. Esparis-Ogando, E. Diaz-Rodriguez, J.C. Montero, L. Yuste, P. Crespo, A. Pandiella, Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol. Cell. Biol. 22(1), 270–285 (2002)PubMedCrossRef
95.
J.C. Montero, A. Ocana, M. Abad, M.J. Ortiz-Ruiz, A. Pandiella, A. Esparis-Ogando, Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. PLoS One 4(5), e5565 (2009)PubMedCrossRef
96.
N.E. Hynes, J.H. Dey, PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough. Cancer Cell 15(5), 353–355 (2009)PubMedCrossRef
97.
B.N. Rexer, R. Ghosh, C.L. Arteaga, Inhibition of PI3K and MEK: it is all about combinations and biomarkers. Clin. Cancer Res. 15(14), 4518–4520 (2009)PubMedCrossRef
98.
B.N. Rexer, J.A. Engelman, C.L. Arteaga, Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle 8(1), 18–22 (2009)PubMedCrossRef
99.
K. Berns, H.M. Horlings, B.T. Hennessy, M. Madiredjo, E.M. Hijmans, K. Beelen, S.C. Linn, A.M. Gonzalez-Angulo, K. Stemke-Hale, M. Hauptmann, R.L. Beijersbergen, G.B. Mills, M.J. van de Vijver, R. Bernards, A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12(4), 395–402 (2007)PubMedCrossRef
100.
C.B. Srikant, S.H. Shen, Octapeptide somatostatin analog SMS 201–995 induces translocation of intracellular PTP1C to membranes in MCF-7 human breast adenocarcinoma cells. Endocrinology 137(8), 3461–3468 (1996)PubMedCrossRef
101.
C. Susini, L. Buscail, Rationale for the use of somatostatin analogs as antitumor agents. Ann. Oncol. 17(12), 1733–1742 (2006)PubMedCrossRef
102.
M.P. Sanderson, P.J. Dempsey, A.J. Dunbar, Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors. Growth Factors 24(2), 121–136 (2006)PubMedCrossRef
Metadata
Title
Cross-talk and modulation of signaling between somatostatin and growth factor receptors
Author
Ujendra Kumar
Publication date
01-10-2011
Publisher
Springer US
Published in
Endocrine / Issue 2/2011
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-011-9524-8

Other articles of this Issue 2/2011

Endocrine 2/2011 Go to the issue

Letter to the Editor

Epidemiology of insulinoma in Tunisia

Original Article

Epidemiologic survey: reference ranges of serum insulin-like growth factor 1 levels in Caucasian adult population with immunoradiometric assay

Mini Review

Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours

Research Letter

Gene expression profiling supports the role of Repin1 in the pathophysiology of metabolic syndrome

Original Article

Factor analysis of modifiable cardiovascular risk factors and prevalence of metabolic syndrome in adult Taiwanese

Original Article

Relationship between Sloan-Kettering virus expression and mouse follicular development
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits